Endocrine Oncology
Read Time: 10 mins

A Review of Evidence that Ultraviolet-B Irradiance and Vitamin D Reduce Risk for Cancer

Copy Link
Published Online: Jun 10th 2013 US Endocrinology, 2013;9(1):50-54 DOI:
Authors: William B Grant
Quick Links:
Article Information

The solar ultraviolet-B (UVB)–vitamin D–cancer hypothesis was proposed in 1980 and has been actively investigated since then. The strongest evidence is from ecologic studies that use indices of solar UVB doses with geographic data on cancer incidence and/or mortality rates. Good evidence also comes from observational studies for breast and colorectal cancer incidence as well as survival rates for several cancers. Laboratory studies have well described the mechanisms whereby vitamin D reduces risk for cancer and increases survival rates after diagnosis. The hypothesis largely satisfies Hill’s criteria for causality for breast and colorectal cancer and moderately satisfies it for several other cancers. However, only two randomized controlled trials (RCTs) found a reduction in cancer incidence for higher vitamin D3 intake. Thus, general acceptance of the UVB–vitamin D–cancer hypothesis will probably be delayed until a large-scale RCT supports it.


Cancer, ecological, Hill


In 1980, the brothers Cedric and Frank Garland proposed the ultraviolet-B (UVB)–vitamin D–cancer hypothesis after observing that US colon cancer mortality rates were lowest in the sunny southwest and highest in the least sunny northeast.1 The evidence that UVB irradiance and vitamin D reduce the risk for many cancers continues to increase. As of March 16, 2013, PubMed included 3,036 entries with vitamin D and cancer in the abstract or title.

In 1980, the brothers Cedric and Frank Garland proposed the ultraviolet-B (UVB)–vitamin D–cancer hypothesis after observing that US colon cancer mortality rates were lowest in the sunny southwest and highest in the least sunny northeast.1 The evidence that UVB irradiance and vitamin D reduce the risk for many cancers continues to increase. As of March 16, 2013, PubMed included 3,036 entries with vitamin D and cancer in the abstract or title. Evidence supporting this hypothesis comes from a variety of studies: ecological, observational, record-linkage, cross-sectional, laboratory, and randomized controlled trials (RCTs). This paper briefly reviews the evidence.

Solar Ultraviolet-B
Ecological studies of cancer incidence and mortality rates using indices of solar UVB doses provide the strongest evidence to date that vitamin D reduces the risk for many cancers. A US study using solar UVB doses at the earth’s surface for July 1992 (determined with a NASA satellite instrument) inversely correlated the mortality rates of 15 cancers with this UVB index.2 That paper included graphs showing that cancer mortality rates for bladder, female breast, and all cancer, less gastric cancer, had nearly linear inverse relations with solar UVB doses for 500 state economic areas, with a slight hint of leveling off at the highest doses. A later study that added other riskmodifying factors (i.e., alcohol consumption, Hispanic heritage, poverty level, smoking, and urban/rural residence) confirmed the results of the first study regarding UVB doses.3 The findings for alcohol consumption and smoking in that study agreed well with what was known then about both’s role in cancer risk. A prospective study of cancer incidence rates for residents of seven states in the US found that living in a state with higher solar UVB doses was associated with increased risk of melanoma and reduced risk for bladder, colon, kidney, squamous-cell lung, pleural, and prostate cancer, as well as non-Hodgkin’s lymphoma, with indications of reduced risk for pancreatic and thyroid cancer.4

Recently a study reported the effects of alcohol consumption on cancer mortality rates, identifying the cancers most affected and that alcohol accounted for about 3.5 % of all cancer deaths.5 The findings in the multifactorial ecological study agreed well with this study.

Many single-country ecological studies have generally made similar findings by using solar UVB doses or latitude as the index of serum 25-hydroxyvitamin D [25(OH)D] concentration. I recently reviewed such studies from Australia, China, France, Japan, and Spain.6 Cancers with the strongest evidence include bladder, breast, cervical, colon, endometrial, esophageal, gastric, lung, ovarian, pancreatic, rectal, renal, and vulvar cancer, as well as Hodgkin’s and non-Hodgkin’s lymphoma. Weaker evidence exists for nine other cancers: brain, gallbladder, laryngeal, oral/ pharyngeal, prostate, and thyroid cancer; leukemia; melanoma; and multiple myeloma (see Table 1).

Occupational studies can also offer evidence of solar UVB’s effect on cancer risk. A recent study used cancer incidence data for 54 occupation categories based on 1.4 million male and 1.36 million female cancer cases for 1961–2005 in the five Nordic countries.23 The index for solar UVB irradiance used was incidence of lip cancer less incidence of lung cancer for males.7 The study used this index for both males and females because women wear lipstick, which reduces UVB irradiance on the lips. This index inversely correlated with both melanoma and nonmelanoma skin cancer (NMSC) for males. This finding is not surprising because sporadic UV

irradiance and chronic UVA irradiance are important risk factors for both melanoma and basal-cell carcinoma,24,25 whereas chronic sun exposure is not.26 This index significantly inversely correlated with 14 internal cancers (see Table 1); for women, the same UVB index was inversely correlated with bladder, breast, and colon cancer.7

UV irradiance is the primary risk factor for NMSC. Thus, diagnosis of or death from NMSC can sometimes serve as an index of high serum 25(OH) D concentration over a prolonged period. Two ecological studies inversely correlated internal cancer mortality rates with NMSC mortality rates: one in Spain for 1978–199227 and one in California for 1950–1964.28 A recordlinkage study also found significant inverse correlations between diagnosis of basal-cell carcinoma and squamous-cell carcinoma in sunny countries (Australia, Singapore, and Spain) and liver, lung, and pancreatic cancer, as well as nonsignificant inverse correlation with bladder, colon, gastric, ovarian, prostate, and renal cancer.8 Diagnosis of these skin cancers directly correlated with all types of cancer in less sunny countries. The likely explanation for the difference between the two types of countries is that sunnier countries are warm enough that people spend more time in the sun and expose more skin area when they do.

Researchers do not consider the ecological approach reliable in general because (1) the ecological approach does not deal with individuals and (2) confounding factors may explain the observed associations. However, for cancer, I find the ecological approach strong. In addition to consistent findings in many countries, other evidence exists that vitamin D reduces cancer risk, and researchers have proposed no mechanism other than vitamin D production to explain the findings of ecological studies. Hill’s criteria for causality in a biologic system offer a way to evaluate the UVB–vitamin D–cancer hypothesis.29 A recent conference in Germany recommended using Hill’s criteria as the basis for evidence-based nutrition.30 The criteria most important for UVB and vitamin D and cancer are strength of association, consistent findings in different populations, biologic gradient (dose–response relation), plausibility (e.g., mechanisms), experiment (e.g., RCTs), analogy, and accounting for confounding factors. These criteria have been examined for cancer in general and found largely satisfied for breast and colorectal cancer, with good evidence that other cancers do as well, including bladder, esophageal, gallbladder, gastric, ovarian, rectal, renal, and uterine corpus cancer, as well as Hodgkin’s and non-Hodgkin’s lymphoma.31 Examining Hill’s criteria for breast cancer, Mohr and colleagues point out that the process of evaluating

evidence for nutrients should be different from that for pharmaceutical drugs, which are evaluated on the tenets of evidence-based medicine.32 They also discussed deficient, adequate, and optimal intakes. Diseases are not deficiencies of pharmaceutical drugs, although many diseases are a consequence of vitamin D deficiency. Also, nearly every cell in the body has a vitamin D receptor. The active metabolite of vitamin D, 1,25-dihydroxyvitamin D (calcitriol), activates the vitamin D receptor and can regulate hundreds of genes.33 No receptors exist for pharmaceutical drugs unless they are specifically targeted.

A recent set of papers in Anti-Cancer Agents in Medical Chemistry reviewed evidence that vitamin D reduced risk for cancer, noting that disagreement remains over strength of the evidence of that assertion. Some studies found no or direct correlations between serum 25(OH)D concentrations and cancer incidence rates, and no strong RCTs have been reported showing that oral vitamin D reduces risk for cancer.34 I present further evidence supporting that hypothesis.

Case–control studies of serum 25(OH)D concentrations have consistently found strong inverse correlations with respect to breast cancer incidence.35 A case–control study found a highly significant inverse correlation between serum 25(OH)D concentration and prevalence of ovarian cancer.36 Although some concern exists that the disease state may affect serum 25(OH)D concentrations, this effect does not seem to be demonstrated for cancer. First, people who have cancer generally do not know so until diagnosis and thus would not change any habits related to vitamin D. Second, when odds ratios for breast or colorectal cancer are plotted versus years of follow-up, findings from case–control studies lie on the regression fit to all the data.37 Also, no studies have shown that cancer tumors reduce 25(OH)D concentrations. Organs afflicted with cancer can still synthesize calcitriol,38 but serum concentrations of calcitriol are about 1/1,000 those of 25(OH)D.

Prospective studies with follow-up times greater than 3 years have found nonsignificant inverse correlations between breast cancer incidence and 25(OH)D concentrations from serum drawn at time of enrollment.37 However, similar prospective studies of colorectal cancer have found significant inverse correlations for follow-up times as long as 12 years.37 The difference between these two cancers is that breast cancer grows much faster. For example, breast cancer diagnosis rates are higher in spring and fall. This finding has been attributed to vitamin D’s reducing risk in summer and melatonin in winter.39

A prospective study of seven cancers with respect to serum 25(OH)D concentration with a mean follow-up time of 9 years found no cancers with an inverse correlation with respect to serum 25(OH)D concentration.40 The problems with this study are not only the long follow-up time but also the few cancer cases. As a result, the 95 % confidence intervals for the odds ratio for the highest quantile of 25(OH)D were 30–50 %. See Grant41 for the relevance of number of cases.

Black Americans have lower cancer-specific and all-cause survival rates after diagnosis of cancer. Many studies have explored these relations, accounting for socioeconomic status, stage at diagnosis, and treatment provided, finding that blacks have survival rates anywhere from zero to 50 % lower than those of white Americans. Such studies were recently reviewed. The difference in population mean serum 25(OH)D concentrations for black Americans (16 ng/ml) and white Americans (26 ng/ml),42 along with the serum 25(OH)D–breast and colorectal cancer incidence relations,11 estimated the disparity in cancer survival rates at 25 %.43

Table 1 summarizes evidence regarding the association of UVB and serum 25(OH)D concentration with respect to cancer incidence, prevalence, survival, or mortality rate. The table omits studies that found either no significant correlation or a direct correlation between UVB or serum 25(OH)D and cancer risk because they are thought to have systematic problems such as too few cases or unaccounted-for confounding factors. The strength of evidence is estimated by the number of types of studies supporting a beneficial role for each cancer. Nine cancers had what I judged to be strong evidence, eight had moderate evidence, and six had weak evidence. One problem with such ranking is that studying the less common cancers is harder because fewer cases are available.41 Most likely, several cancers with evidence ranked as moderate could be considered strongly affected by UVB and vitamin D. Table 2 gives an overview of strengths and weaknesses of various study types regarding vitamin D and risk for cancer.

Studies have identified several mechanisms that explain how vitamin D reduces risk for cancer incidence and increases survival after cancer initiation. These effects are made by 1,25-dihydroxyvitamin D, generally by activating the vitamin D receptor. This active metabolite of vitamin D exerts several effects on cells, including controlling cellular proliferation and apoptosis. Vitamin D helps with calcium absorption, and calcium reduces risk for cancer.49 Vitamin D also reduces metastasis and angiogenesis around tumors. The literature includes several good reviews of vitamin D–cancer reduction mechanisms.50–52 The Garland group proposed a comprehensive model to explain how vitamin D reduces risk for cancer: “Its seven phases are disjunction, initiation, natural selection, overgrowth, metastasis, involution, and transition (abbreviated DINOMIT). Vitamin D metabolites prevent disjunction of cells and are beneficial in other phases”.50

Randomized Controlled Trials
Two vitamin D and calcium supplementation RCTs found reduced risk for cancer incidence. The first was conducted on postmenopausal women in Nebraska. They were divided into three arms: placebo, 1,450 mg of calcium per day, and 1,450 mg of calcium plus 1,100 IU of vitamin D3 per day.46 Between the ends of the first and fourth years, those taking calcium had a 41 % (95 % confidence interval [CI], −21 % to 71 %) reduced risk for all-cancer incidence, whereas those taking vitamin D plus calcium had a 77 % (95 % CI, 40 % to 91 %) reduction. Thus, a 36 % reduction occurred that could be attributed to vitamin D. In this study, that oral intake was associated with an increase in serum 25(OH)D concentration from 71.8 to 96.0 nmol/l. According to the graphical meta-analysis of the odds ratio of breast cancer incidence with respect to serum 25(OH)D concentration from case–control studies, the expected change in serum 25(OH)D concentration is 20 %. This value, which also has considerable uncertainty, generally agrees with the Nebraska results.

The second study was a reanalysis from the Women’s Health Initiative. This study considered only women who had not been taking personal vitamin D or calcium supplements before enrolling in the study. It reported the following: “In 15,646 women (43 %) who were not taking personal calcium or vitamin D supplements at randomization, CaD [calcium and vitamin D] significantly decreased the risk for total, breast, and invasive breast cancers by 14–20 % and nonsignificantly reduced the risk for colorectal cancer by 17 %. In women taking personal calcium or vitamin D supplements, CaD did not alter cancer risk (HR: 1.06–1.26)”.47 The general problem with vitamin D RCTs to date is that they have not been well designed. Lappe and Heaney48 outlined considerations for proper vitamin D RCTs:

  • Start with an estimated serum 25(OH)D concentration–health outcome relation.
  • Enroll people in the study who have serum 25(OH)D concentrations near the low end of the relation.
  • Supplement them with enough vitamin D to raise serum 25(OH)D concentration to near the upper end of the relation.
  • Consider other sources of vitamin D.
  • Remeasure serum 25(OH)D concentrations during or at study end.

So few RCTs have followed these guidelines that when the Institute of Medicine reviewed the evidence that vitamin D reduced risk for adverse health outcomes, it found convincing evidence from RCTs only for bones.53

Another problem is that the time of life when vitamin D or diet is beneficial may be at a much younger age than that of those enrolled in RCTs, and determining whether younger people were used may take many years. Several studies found reduced risk for cancer for those with higher solar UVB irradiance in youth or early adulthood.59 A multicountry ecological study found that animal fat in the national dietary supply was highly correlated with rates for many cancers.55 This finding was disputed for nearly 3 decades until cohort studies found that animal products were an important risk factor for breast cancer for younger women.56 Studies of risk factors for Alzheimer’s disease should enroll people for 40 years.57

Ultraviolet Irradiance and Vitamin D Concerns
Because the strongest evidence that vitamin D reduces cancer risk comes from ecological studies based on indices of solar UVB doses, people could be advised to spend more time in the sun.58 Although doing so entails risk for skin cancer and melanoma, the risk should be minimal for those with skin type suited for the UV dose where they live.59 One should not stay in the sun long enough to develop erythema, or reddening.

Concerns have emerged about adverse health effects of serum 25(OH)D concentrations above 30 ng/ml, on the basis of finding U-shaped relations between serum 25(OH)D concentration and health outcome such as mortality rate.60 Some studies do not find statistically significantly increased risks at higher concentrations, whereas others are not consistent with most other studies on the same topic. A possible explanation for some of the findings is that study participants with higher serum 25(OH)D concentrations may have been diagnosed with a vitamin D–deficiency disease such as osteoporosis and advised by their physician to supplement with vitamin D. This was most likely the case for women in a US frailty study61 because men had an inverse correlation between serum 25(OH)D concentration and frailty status.62

Other Benefits of Vitamin D
Good observational evidence shows that higher serum 25(OH)D concentrations reduces risk for many adverse health outcomes, including all-cause mortality rate,63 cardiovascular disease,64,65 and type 2 diabetes mellitus.66

In light of the rapidly mounting evidence that serum 25(OH)D concentrations above 30–40 ng/ml are associated with better health outcomes,67–69 people should try to reach those levels through a combination of moderate solar UVB irradiance and vitamin D supplementation. Considerable variation exists in serum 25(OH) D concentration for any oral vitamin D intake,70 so people can either take 1,000–4,000 IU of vitamin D per day69–70 or have serum 25(OH) D concentration measured before starting to increase 25(OH)D concentrations, then again after several months. For reference, US mean population serum 25(OH)D concentrations in the early 2000s were 16 ng/ml for black Americans, 21 ng/ml for Hispanic Americans, and 26 ng/ml for white Americans.42 Thus, about two-thirds of Americans had suboptimal serum 25(OH)D concentrations then, and with the rising prevalence of obesity, the fraction is probably higher now. Serum 25(OH) D concentrations above 30–40 ng/ml confer many health benefits, along with virtually no substantiated health risks below 100 ng/ml. And vitamin D supplements are inexpensive. Therefore, implementing these recommendations makes good public-health sense.

Article Information:

William B Grant receives funding from Bio-Tech Pharmacal (Fayetteville, AR) and the Sunlight Research Forum (Veldhoven) and has received funding from the UV Foundation (McLean, VA), the Vitamin D Council (San Luis Obispo, CA), and the Vitamin D Society (Canada).


William B Grant, PhD, Director, Sunlight, Nutrition, and Health Research Center, San Francisco, CA 94164-1603, US. E:




1. Garland CF, Garland FC, Do sunlight and vitamin D reduce the likelihood of colon cancer?, Int J Epidemiol, 1980;9(3):227–31.
2. Grant WB, An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation, Cancer, 2002;94(6):1867–75.
3. Grant WB, Garland CF, The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates, Anticancer Res, 2006;26(4A):2687–99.
4. Lin SW, Wheeler DC, Park Y, et al., Prospective study of ultraviolet radiation exposure and risk of cancer in the U.S, Int J Cancer, 2012;131(6):E1015–23.
5. Nelson DE, Jarman DW, Rehm J, et al., Alcohol-attributable cancer deaths and years of potential life lost in the United States, Am J Public Health, 2013;103(4):641–8.
6. Grant WB, Ecological studies of the UVB–vitamin D–cancer hypothesis; review, Anticancer Res, 2012;32(1):223–36.
7. Grant WB, Role of solar UV irradiance and smoking in cancer as inferred from cancer incidence rates by occupation in Nordic countries, Dermatoendocrinol, 2012;4(2):203–11.
8. Tuohimaa P, Pukkala E, Scelo G, et al., Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: Vitamin D as a possible explanation, Eur J Cancer, 2007;43:1701–1712.
9. Mondul AM, Weinstein SJ, Männistö S, et al., Serum vitamin D and risk of bladder cancer, Cancer Res, 2010;70 9218–23.
10. Peiris AN, Bailey BA, Manning T, Relationship of vitamin D monitoring and status to bladder cancer survival in veterans, South Med J, 2013;106(2):126–30.
11. Grant WB, Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers, J Photochem Photobiol B, 2010;101(2):130–36.
12. Yang L, Veierod MB, Lof M, et al., Prospective study of UV exposure and cancer incidence among Swedish women, Cancer Epidemiol Biomarkers Prev, 2011;20(7);1358–67.
13. Tretli S, Schwartz GG, Torjesen PA, Robsahm TE, Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study, Cancer Causes Control, 2012;23(2):363–70.
14. Epstein E, Lindqvist PG, Geppert B, Olsson H, A population-based cohort study on sun habits and endometrial cancer, Br J Cancer, 2009;101(3):537–40.
15. Tran B, Lucas R, Kimlin M, et al., Association between ambient ultraviolet radiation and risk of esophageal cancer, Am J Gastroenterol, 2012;107:1803–13.
16. Ren C, Qiu MZ, Wang DS, et al., Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer, J Transl Med, 2012;10(1):16.
17. Cheng TY, Neuhouser ML, Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient-nutrient interaction, Cancer Causes Control, 2012;23(9):1557–65.
18. Toriola AT, Surcel HM, Calypse A, et al., Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: A prospective nested case-control study, Eur J Cancer, 2010;46(15):2799–805.
19. Tran B, Jordan SJ, Lucas RM, et al., Association between ambient ultraviolet radiation and risk of epithelial ovarian cancer, Cancer Prev Res (Phila), 2012;5(11):1330–36.
20. Wolpin BM, Ng K, Bao Y, et al., Plasma 25-hydroxyvitamin D and risk of pancreatic cancer, Cancer Epidemiol Biomarkers Prev, 2012;21(1):82–91.
21. Gilbert R, Metcalfe C, Fraser WD, et al., Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade, Int J Cancer, 2012;131(5):1187–96.
22. Salehin D, Haugk C, Thill M, et al., Serum 25-hydroxyvitamin D levels in patients with vulvar cancer, Anticancer Res, 2012;32 265–70.
23. Pukkala E, Martinsen JI, Lynge E, et al., Occupation and cancer – follow-up of 15 million people in five Nordic countries, Acta Oncol, 2009;48:646–790.
24. Garland CF, Garland FC, Gorham ED, Epidemiologic evidence for different roles of ultraviolet A and B radiation in melanoma mortality rates, Ann Epidemiol, 2003;13(6):395–404.
25. Lin JS, Eder M, Weinmann S, et al., Behavioral counseling to prevent skin cancer: Systematic evidence review to update the 2003 U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Feb.
26. Chang YM, Barrett JH, Bishop DT, et al., Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls, Int J Epidemiol, 2009;38(3):814–30.
27. Grant WB, An ecologic study of cancer mortality rates in Spain with respect to indices of solar UV irradiance and smoking, Int J Cancer, 2007;120(5):1123-7.
28. Grant WB, An ecological study of cancer mortality rates in California, 1950–64, with respect to solar UVB and smoking indices, Dermatoendocrinol, 2012;4(2):176–82.
29. Hill AB, The environment and disease: Association or causation?, Proc R Soc Med, 1965;58:295–300.
30. Biesalski HK, Aggett PJ, Anton R, et al., 26th Hohenheim Consensus Conference, September 11, 2010 Scientific substantiation of health claims: evidence-based nutrition, Nutrition, 2011;27(10 Suppl.):S1–20.
31. Grant WB, How strong is the evidence that solar ultraviolet B and vitamin D reduce the risk of cancer? An examination using Hill’s criteria for causality, Dermatoendocrinol, 2009;1(1):17–24.
32. Mohr SB, Gorham ED, Alcaraz JE, et al., Does the evidence for an inverse relationship between serum vitamin D status and breast cancer risk satisfy the Hill criteria?, Dermatoendocrin, 2012;4(2):152–7.
33. Pike JW, Meyer MB, The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D3, Rheum Dis Clin North Am, 2012;38(1):13–27.
34. Pilz S, Vitamin D and cancer: current evidence and future perspective, Anticancer Agents Med Chem, 2013;13(1):2–3.
35. Grant WB, A review of the evidence regarding the solar ultraviolet-B–vitamin D–cancer hypothesis, Standardy Medyczne/ Pediatria, 2012;9:610–19.
36. Bakhru A, Mallinger JB, Buckanovich RJ, Griggs JJ, Casting light on 25-hydroxyvitamin D deficiency in ovarian cancer: A study from the NHANES, Gynecol Oncol, 2010;119(2):314–18.
37. Grant WB, Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin D level; implications for meta-analyses and setting vitamin D guidelines, Dermatoendocrinol, 2011;3(3):199– 204.
38. Zehnder D, Bland R, Williams MC, et al., Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase, J Clin Endocrinol Metab, 2001;86(2):888–94.
39. Oh EY, Ansell C, Nawaz H, et al., Global breast cancer seasonality, Breast Cancer Res Treat, 2010;123(1):233–43.
40. Helzlsouer KJ, For the VDPP Steering Committee. Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, Am J Epi, 2010;172:4–9.
41. Grant WB, An ecological study of cancer mortality rates in the United States with respect to solar ultraviolet-B doses, smoking, alcohol consumption, and urban/rural residence, Dermatoendocrinol, 2010;2(2):68–76.
42. Ginde AA, Liu MC, Camargo CA Jr, Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004, Arch Intern Med, 2009;169(6):626–32.
43. Grant WB, Peiris AN, Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and White Americans, Dermatoendocrinol, 2012;4(2):85–94.
44. Grant WB, Effect of follow-up time on the relation between prediagnostic serum 25-hydroxyitamin D and all-cause mortality rate, Dermatoendocrinol, 2012;4(2):198–202.
45. Fleet JC, Desmet M, Johnson R, Li Y, Vitamin D and cancer: a review of molecular mechanisms, Biochem J, 2012;441(1):61–76.
46. Lappe JM, Travers-Gustafson D, Davies KM, et al., Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial, Am J Clin Nutr, 2007;85(6):1586–91.
47. Bolland MJ, Grey A, Gamble GD, Reid IR, Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set, Am J Clin Nutr, 2011;94(4):1144–9.
48. Lappe JM, Heaney RP, Why randomized controlled trials of calcium and vitamin D sometimes fail, Dermatoendocrin, 2012;4(2):95–100.
49. Peterlik M, Grant WB, Cross HS, Calcium, vitamin D and cancer, Anticancer Res, 2009;29(9):3687–98.
50. Garland CF, Gorham ED, Mohr SB, Garland FC, Vitamin D for cancer prevention: Global perspective, Ann Epi, 2009;19(7): 468–83.
51. Mocellin S, Vitamin D and cancer: Deciphering the truth, Biochim Biophys Acta, 2011;1816(2):172–8.
52. Krishnan AV, Trump DL, Johnson CS, Feldman D, The role of vitamin D in cancer prevention and treatment, Rheum Dis Clin North Am, 2012;38(1):161–78.
53. Ross AC, Manson JE, Abrams SA, et al., The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know, J Clin Endocrinol Metab, 2011;96(1):53–8.
54. Grant WB, Benefits of ultraviolet-B irradiance and vitamin D in youth, J Steroid Biochem Molec Bio, 2012; Epub ahead of print.
55. Armstrong B, Doll R, Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices, Int J Cancer, 1975;15(4):617–31.
56. Cho E, Chen WY, Hunter DJ, et al. Red meat intake and risk of breast cancer among premenopausal women, Arch Intern Med, 2006;166(20):2253–9.
57. Friedland RP, Nandi S, A modest proposal for a longitudinal study of dementia prevention (with apologies to Jonathan Swift, 1729), J Alzheimers Dis, 2013;33(2):313–15.
58. Grant WB, In defense of the sun: An estimate of changes in mortality rates in the United States if mean serum 25-hydroxyvitamin D levels were raised to 45 ng/mL by solar ultraviolet-B irradiance. Dermatoendocrinol, 2009;1(4):207–14.
59. Jablonski NG, Chaplin G. Colloquium paper: human skin pigmentation as an adaptation to UV radiation, Proc Natl Acad Sci U S A, 2010;107 Suppl 2:8962–8.
60. Durup D, Jørgensen HL, Christensen J, et al., A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice, the CopD Study, J Clin Endocrinol Metab, 2012;97(8):2644–52.
61. Ensrud KE, Ewing SK, Fredman L, et al., Circulating 25-hydroxyvitamin D levels and frailty status in older women, J Clin Endocrinol Metab, 2010;95(12):5266–73.
62. Ensrud KE, Blackwell TL, Cauley JA, et al., Circulating 25-hydroxyvitamin D levels and frailty in older men: the osteoporotic fractures in men study, J Am Geriatr Soc, 2011;59(1):101–6.
63. Zittermann A, Iodice S, Pilz S, et al., Vitamin D deficiency and mortality risk in the general population: A meta-analysis of prospective cohort studies, Am J Clin Nutr, 2012;95(1):91–100.
64. Anderson JL, May HT, Horne BD, et al., Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population, Am J Cardiol, 2010;106(7):963–8.
65. Vacek JL, Vanga SR, Good M, et al., Vitamin D deficiency and supplementation and relation to cardiovascular health, Am J Cardiol, 2012;109(3):359–63.
66. Afzal S, Bojesen SE, Nordestgaard BG, Low 25-hydroxyvitamin D and risk of type 2 diabetes: A prospective cohort study and metaanalysis, Clin Chem, 2013;59(2):381–91
67. Souberbielle JC, Body JJ, Lappe JM, et al., Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice, Autoimmun Rev, 2010;9(11):709–15.
68. Grant WB, An estimate of the global reduction in mortality rates through doubling vitamin D levels, Eur J Clin Nutr, 2011;65(9):1016–26.
69. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al., Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab, 2011;96(7):1911–30.
70. Garland CF, French CB, Baggerly LL, Heaney RP, Vitamin D supplement doses and serum 25-hydroxyvitamin D in the range associated with cancer prevention, Anticancer Res, 2011;31:617–22.

Further Resources

Share this Article
Related Content In Endocrine Oncology
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72